Cannabis Chewing Gum Clinical Trials Secure Funding to Treat Irritable Bowel Syndrome, MS

AXIM Biotechnologies received $4 million in institutional funding to advance clinical trials for cannabis chewing gum for the treatment of irritable bowel syndrome (IBS) and pain and spasticity in multiple sclerosis (MS). The secured funds will also allow the company to continue its bioequivalency study.
The bioequivalency study seeks to develop the prototype chewing gum, MedChew Dronabinol, as an alternative to dronabinol (Marinol) for the treatment of chemotherapy-induced nausea and loss of appetite.
“This financing enables us to continue to build on the progress we have made with our cannabinoid clinical development program for indications where there are currently no effective treatments,” George Anastassov, MD, DDS, MBA, chief executive officer of AXIM, said in a press release. “It is encouraging to see that investors recognize the potential of our robust clinical development pipeline. We are now better positioned to execute on cannabinoid research and commercialization.”
 ... read more at:

Leave a Reply

Your email address will not be published. Required fields are marked *